An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation

Drug Metabolism Reviews

Volumn 30, Issue 4, 1998, Pages 709-737

  Lewis, D F V ^a   Ioannides, C ^a   Parke, D V ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AROMATIC HYDROCARBON; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CLOFIBRATE; CYTOCHROME P450; DEXAMETHASONE; DRUG; ELLIPTICINE DERIVATIVE; HALOTHANE; METYRAPONE; NIFEDIPINE; ORGANIC SOLVENT; PARACETAMOL; PROADIFEN; PROTEIN; QUINIDINE; TESTOSTERONE; XENOBIOTIC AGENT;

ANALYTIC METHOD; CHEMICAL STRUCTURE; DRUG ACTIVATION; DRUG STRUCTURE; ENZYME SPECIFICITY; MOLECULAR MODEL; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; REVIEW;

EID: 0031754690     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.3109/03602539808996328     Document Type: Review

References (51)

1. D. F. V. Lewis, and G. R. Langley, A validation study of the COMPACT and Hazard expert techniques with 40 chemicals, Mutat. Res., 469, 157-174 (1996).
2. D. F. V. Lewis, The Cytochromes P450: Structure, Function and Mechanism, Taylor and Francis, London, 1996.
3. D. F. V. Lewis, COMPACT and the importance of frontier orbitals in toxicity mediated by the cytochrome P450 mono-oxygenase system, Toxicol. Model., 1., 85-97 (1995).
4. D. F. V. Lewis, H. Moereels, B. G. Lake, C. Ioannides, and D. V. Parke, Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D, Drug Metab. Rev., 26, 261-285 (1994).
5. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Molecular modelling of cytochrome P4501: A putative access channel explains differences in induction potency between the isomers benzo(a)pyrene and benzo(e)pyrene and 2- and 4-acetylaminofluorene, Toxicol. Lett., 71, 235-243 (1994).
6. C. Ioannides, Y.-L. Cheung, J. P. Wilson, D. F. V. Lewis, and T. J. B. Gray, Importance of cytochrome P450 induction in chemical carcinogenesis: The case for 2- and 4-acetylaminofluorene, Chem. Res. Toxicol., 6, 535-541 (1993).
7. G. W. Boyd, M. M. Coombs, and C. Ioannides, CYP1 induction, binding to the hepatic aromatic hydrocarbon receptor and mutagenicity of a series of 11-alkoxy cyclopenta[a]phenanthren-17-ones: A structure activity relationship, Toxicology, 95, 27-35 (1995).
8. D. F. V. Lewis, Quantitative structure-activity relationships in substrates, inducers and inhibitors of cytochromes P4501 (CYP1), Drug Metab. Rev., 29, 589-650 (1997).
9. S. J. Roffey, Structure-activity relationships in the metabolism of a series of tertiary amines by cytochrome P450, Ph.D. thesis, University of Surrey, 1993.
10. D. F. V. Lewis and B. G. Lake, Molecular modelling of CYP2B isoforms and their interaction with substrates, inhibitors and redox components, Xenobiotica, 27, 443-478 (1997).
11. D. F. V. Lewis, Molecular modelling of cytochromes P450, in Computer-Assisted Lead Finding and Optimization (H. van de Waterbeemd, B. Testa, and G. Folkers, eds.), Verlag Helvetica Acta, Basel, 1997, Chap. 21, pp. 333-354.
12. D. F. V. Lewis, C. Ioannides, D. V. Parke, and R. Walker, Quantitative structure-activity relationships in some cooked food mutagens. Food Addit. Contam., 12, 715-724 (1995).
13. D. F. V. Lewis and D. V. Parke, The genotoxicity of benzanthracenes: A quantitative structure-activity study, Mutat. Res., 328, 207-214 (1995).
14. D. F. V. Lewis, B. G. Lake, C. Ioannides, and D. V. Parke, Inhibition of hepatic aryl hydrocarbon hydroxylase activity by a series of 7-hydroxy coumarins: QSAR studies, Xenobiotica, 24, 829-838 (1994).
15. D. F. V. Lewis, B. G. Lake, and D. V. Parke, Molecular orbital-generated QSARs in a homologous series of alkoyresorufins and studies of their interactive docking with P450s, Xenobiotica, 25, 1355-1369 (1995).
16. D. F. V. Lewis, C. Ioannides, and D. V. Parke, A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4) and also their hydroxylation rates, Biochem. Pharmacol., 50, 619-625 (1995).
17. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Interaction of a series of nitriles with the alcohol inducible isoform of cytochrome P450: Computer analysis of structure-activity relationships, Xenobiotica, 24, 401-408 (1994).
18. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Computer graphics analysis of the interaction of alkoxy methylene dioxybenzenes with cytochromes P4501, Toxicol. Lett., 76, 39-45 (1995).
19. D. F. V. Lewis, Molecular modelling, in Food Chemical Risk Analysis (D. R. Tennant, ed.), Chapman & Hall, London, Chap. 7, pp. 163-194, 1997.
20. D. F. V. Lewis, C. Ioannides, and D. V. Parke, A retrospective evaluation of COMPACT predictions of rodent carcinogenicity testing from the NTP rodent bioassay results of 40 chemicals, Environ. Health Perspect., 103, 178-184 (1995).
21. D. F. V. Lewis, M. G. Bird, and D. V. Parke, Molecular modelling of P, CYP2E1 enzymes from rat, mouse and man: A possible explanation for the species differences in butadiene metabolism, Toxicology, 118, 93-113 (1997).
22. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Validation of a novel molecular orbital approach (COMPACT) to the safety evaluation of chemicals by comparison with salmonella mutagenicity and rodent carcinogenicity data evaluated by the US NCI/NTP, Mutat. Res., 291, 61-77 (1993).
23. D. F. V. Lewis, Comparison between rodent carcinogenicity test results of 44 chemicals and a number of predictive systems, Regul. Toxicol. Pharmacol., 20, 215-222 (1994).
24. S. J. Brown, A. A. Raja, and D. F. V. Lewis, A comparison between COMPACT and HazardExpert evaluations for 80 chemicals tested by the NTP/ NCI rodent bioassay, ATLA, 22, 482-500 (1994).
25. K. T. Bogen, Improved prediction of carcinogenic potencies from mutagenic potencies for chemicals positive in rodents and the Ames test, Environ. Molec. Mutagen., 25, 37-49 (1995).
26. D. F. V. Lewis and B. G. Lake, The interaction of some peroxisome proliferators with the mouse liver peroxisome proliferator-activated receptor (ppar): A molecular modelling and quantitative structure-activity relationship study, Xenobiotica, 23, 79-96 (1993).
27. D. F. V. Lewis and B. G. Lake, A quantitative structure-activity relationship (QSAR) analysis for a series of rodent peroxisome proliferators: Interaction with the mouse liver peroxisome proliferator-activated receptor α (mPPARα), Toxicol. in Vitro, 11, 99-105 (1997).
28. D. F. V. Lewis, M. G. Parker, and R. J. B. King, Interactions based on molecular modelling of the human estrogen receptor and ligand site-directed mutagenesis and amino acid sequence homology, J. Steroid Biochem. Molec. Biol., 25, 55-65 (1995).
29. D. F. V. Lewis, Three-dimensional models of human and other mammalian P450s constructed from an alignment with P450102 (P450bm3), Xenobiotica, 25, 333-366 (1995).
30. D. F. V. Lewis and B. G. Lake, Molecular modelling of members of the P4502A subfamily: Application to studies of enzyme specificity, Xenobiotica, 25, 585-598 (1995).
31. D. F. V. Lewis and B. G. Lake, Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: Rationalization of CYP1A substrate specificity in terms of active site amino acid residues, Xenobiotica, 26, 723-753 (1996).
32. D. F. V. Lewis, P. J. Eddershaw, P. S. Goldfarb, and M. H. Tarbit, Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals, Xenobiotica, 26, 1067-1086 (1996).
33. H. Wiseman and D. F. V. Lewis, The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: Potential importance to its proposed anticarcinogenic/carcinogenic actions, Carcinogenesis, 17, 1357-1360 (1996).
34. C. Ioannides and D. V. Parke, Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis, Drug Metab. Rev., 25, 485-501 (1993).
35. D. F. V. Lewis and B. G. Lake, Molecular modelling of omeprazole interactions with cytochrome P450 isozymes is consistent with metabolism in human liver microsomes, Toxicology, 125, 31-44 (1998).
36. T. Andersson, J. O. Miners, W. Tassaneeyakul, W. Tassaneeyakul, U. A. Meyer, and D. J. Birkett, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism, Br. J. Clin. Pharmacol., 36, 521-530 (1993).
37. M. Rossi, S. Markovitz, and T. Callahan, Defining the active site of cytochrome P450: The crystal and molecular structure of an inhibitor, SKF-525A, Carcinogenesis, 8, 881-887 (1987).
38. M. Roy, N. Fernandez, and P. Lesca, Binding characteristics of 4-S proteins from rat and mouse liver, Eur. J. Biochem., 172, 593-599 (1988).
39. J. P. Landers and N. J. Bunce, The Ah receptor and the mechanism of dioxin toxicity, Biochem. J., 276, 273-287 (1991).
40. E. Bresnick and W. H. Houser, The induction of cytochrome P450c by polycyclic hydrocarbons proceeds through the interaction of a 4S cytosolic binding protein, Front. Biotransform., 2, 62-81 (1990).
41. F. P. Guengerich, Human cytochrome P450 enzymes, in Cytochrome P450 (P. R. Ortiz de Montellano, ed.), Plenum, New York, Chap. 14, pp. 473-535.
42. D. F. V. Lewis, Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P450 mediated aniline hydroxylation, Chem.-Biol. Interact., 62, 271-280 (1987).
43. D. F. V. Lewis, The calculation of molar polarizabilities by the CNDO/2 method: Correlation with the hydrophobic parameter, log P, J. Comput. Chem., 10, 145-151 (1989).
44. C. Hansch, and A. Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology, Wiley, New York, 1979.
45. J. Sangster, Octanol-water partition coefficients of simple organic compounds, J. Phys. Chem. Ref. Data, 18, 1111-1229 (1989).
46. C. Hansch, J. P. Bjorkroth, and A. Leo, Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design, J. Pharmaceut. Sci., 76, 663-687 (1987).
47. T. Suzuki and Y. Kudo, Automatic log P estimation based on combined additive modeling methods, J. Computer-Aided Molec. Des., 4, 155-198 (1990).
48. R. F. Rekker, A. M. ter Laak, and R. Mannhold, On the reliability of calculated log P values: Rekker, Hansch/Leo and Suzuki approach, Quant. Structure-Activity Relationships, 12, 152-157 (1993).
49. J. G. Vinter, A. Davis, and M. R. Saunders, Strategic approaches to drug design. 1. An integrated software framework for molecular modelling, J. Computer-Aided Molec. Design, 1, 31-51 (1987).
50. I. Fleming, Frontier Orbitals and Organic Chemical Reactions, Wiley, New York, 1980.
51. A. H. Conney, Factors influencing benzo(a)pyrene metabolism in animals and man, in Chemical Carcinogenesis (P. O. P. Ts'O and J. A. Di Paolo, eds.), Marcel Dekker, New York, 1974, pp. 353-369.